KAM
ALNY icon

Kazazian Asset Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Kazazian Asset Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,000
Closed -$235K – 62
2024
Q4 		$235K Buy
+1,000
New +$263K 0.18% 50

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Kazazian Asset Management's ALNY Position: Q1 2025 in Review

Kazazian Asset Management sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2025, closing a stake of 1,140 shares — an estimated $268K sold.

Kazazian Asset Management first reported a position in ALNY in Q4 2024 and held it in 1 quarter. The position peaked at $268K in Q4 2024. 627 funds tracked by Wall St. Rank hold ALNY as of Q1 2025.

  • Kazazian Asset Management reported no remaining Alnylam Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Kazazian Asset Management sold 1,140 Alnylam Pharmaceuticals shares in Q1 2025, an estimated $268K.
  • Kazazian Asset Management first reported a position in Alnylam Pharmaceuticals in Q4 2024 and held it in 1 quarter.
  • Kazazian Asset Management's Alnylam Pharmaceuticals position peaked at $268K in Q4 2024.
  • 627 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2025.

Based on Kazazian Asset Management's 13F filing for Q1 2025, filed 9 May 2025.